Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Odenholt-Tornqvist I et al. | Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. | 1995 | Antimicrob. Agents Chemother. | pmid:7695310 |
| Malinverni R et al. | Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. | 1995 | Antimicrob. Agents Chemother. | pmid:7695327 |
| Hunter RP et al. | Pharmacokinetics, oral bioavailability and tissue distribution of azithromycin in cats. | 1995 | J. Vet. Pharmacol. Ther. | pmid:7752305 |
| Ives DV et al. | Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. | 1995 | AIDS | pmid:7755914 |
| Onyeji CO et al. | Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. | 1995 | J. Infect. Dis. | pmid:7658075 |
| Debets-Ossenkopp YJ et al. | Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. | 1995 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:7649202 |
| Adal KA et al. | Photo quiz. Bacillary angiomatosis. | 1995 | Clin. Infect. Dis. | pmid:7727641 |
| Bermudez LE et al. | Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice. | 1995 | J. Antimicrob. Chemother. | pmid:8591938 |
| Domingo S et al. | Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice. | 1995 | J. Antimicrob. Chemother. | pmid:8591939 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Gill CJ et al. | In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin. | 1995 | J. Antibiot. | pmid:7490222 |
| Silvestri M et al. | Azithromycin induces in vitro a time-dependent increase in the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes without damaging phagocytes. | 1995 | J. Antimicrob. Chemother. | pmid:8821593 |
| Patton DL et al. | The activity of azithromycin on the infectivity of Chlamydia trachomatis in human amniotic cells. | 1995 | J. Antimicrob. Chemother. | pmid:8821594 |
| Spangler SK et al. | Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies. | 1995 | J. Clin. Microbiol. | pmid:7615756 |
| Ramadan MA et al. | Post-antibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis. | 1995 | J. Med. Microbiol. | pmid:7752216 |
| Tissi L et al. | In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. | 1995 | Antimicrob. Agents Chemother. | pmid:8540695 |
| Mégraud F et al. | [Helicobacter pylori and azithromycin]. | 1995 | Pathol. Biol. | pmid:8539082 |
| Derouin F | [New pathogens and mode of action of azithromycin: Toxoplasma gondii]. | 1995 | Pathol. Biol. | pmid:8539083 |
| Perronne C | [Azithromycin and Mycobacterium avium infection]. | 1995 | Pathol. Biol. | pmid:8539084 |
| Edelstein PH | Review of azithromycin activity against Legionella spp. | 1995 | Pathol. Biol. | pmid:8539085 |
| Oh YK et al. | Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. | 1995 | Antimicrob. Agents Chemother. | pmid:8540724 |
| Clancy J et al. | Assays to detect and characterize synthetic agents that inhibit the ErmC methyltransferase. | 1995 | J. Antibiot. | pmid:8557568 |
| Amsden GW | Macrolides versus azalides: a drug interaction update. | 1995 | Ann Pharmacother | pmid:8547740 |
| Kuschner RA et al. | Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. | 1995 | Clin. Infect. Dis. | pmid:8527539 |
| Wahlstrom E et al. | Improvement in cyclosporine-associated gingival hyperplasia with azithromycin therapy. | 1995 | N. Engl. J. Med. | pmid:7854392 |
| Beckers CJ et al. | Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. | 1995 | J. Clin. Invest. | pmid:7814637 |
| Friis HM | [Azithromycin--an exciting new antibiotic]. | 1995 | Ugeskr. Laeg. | pmid:7831724 |
| Tajima T et al. | [Pharmacokinetic and clinical studies with azithromycin (fine granule) in the pediatric field. Pediatric Study Group of Azithromycin]. | 1995 | Jpn J Antibiot | pmid:7474329 |
| Dessau RB | [Azithromycin]. | 1995 | Ugeskr. Laeg. | pmid:7831733 |
| Fujii R et al. | [Pharmacokinetic and clinical studies with azithromycin (capsule) in the pediatric field. Pediatric Study Group of Azithromycin]. | 1995 | Jpn J Antibiot | pmid:7474330 |
| Sasaki J et al. | [Comparative clinical study of azithromycin with tosufloxacin tosilate in the treatment of acute odontogenic infection]. | 1995 | Jpn J Antibiot | pmid:7474331 |
| Uchino U et al. | [Effects of azithromycin on fecal flora of healthy adult volunteers]. | 1995 | Jpn J Antibiot | pmid:7474332 |
| Toscano MA et al. | [Efficacy and tolerance of azithromycin in respiratory tract infections in children]. | 1995 | Minerva Pediatr. | pmid:7476752 |
| Bowden FJ et al. | Azithromycin and syphilis. | 1995 | Genitourin Med | pmid:7635501 |
| Yeo AE and Rieckmann KH | Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro. | 1995 | Int. J. Parasitol. | pmid:7635629 |
| Bamberger DM et al. | Azithromycin in an experimental Staphylococcus aureus abscess model. | 1995 | J. Antimicrob. Chemother. | pmid:7592175 |
| Adegbola RA et al. | Effect of azithromycin on pharyngeal microflora. | 1995 | Pediatr. Infect. Dis. J. | pmid:7603826 |
| Vartiovaara I | Living with Lyme. | 1995 | Lancet | pmid:7605437 |
| Fouda HG and Schneider RP | Quantitative determination of the antibiotic azithromycin in human serum by high-performance liquid chromatography (HPLC)-atmospheric pressure chemical ionization mass spectrometry: correlation with a standard HPLC-electrochemical method. | 1995 | Ther Drug Monit | pmid:7624907 |
| Goldstein EJ et al. | Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. | 1995 | Antimicrob. Agents Chemother. | pmid:7625795 |
| Barry AL et al. | Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics. | 1995 | J. Antimicrob. Chemother. | pmid:7628991 |
| Stamm WE et al. | Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. | 1995 | JAMA | pmid:7629982 |
| Schmid GP and Fontanarosa PB | Evolving strategies for management of the nongonococcal urethritis syndrome. | 1995 | JAMA | pmid:7629989 |
| Sadiq ST et al. | Effects of azithromycin on malariometric indices in The Gambia. | 1995 | Lancet | pmid:7564674 |
| Wawer MJ et al. | AIDS intervention in Uganda. | 1995 | Science | pmid:7570005 |
| Worm AM and Osterlind A | Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis. | 1995 | Genitourin Med | pmid:7590717 |
| Gastearena I et al. | Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro by equilibrium dialysis. | 1995 | J Chemother | pmid:8904095 |
| Domingo S et al. | Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. | 1995 | J Chemother | pmid:8904096 |
| Van Asselt GJ et al. | Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. | 1995 | J. Med. Microbiol. | pmid:7563004 |
| Bessette RE and Amsden GW | Treatment of non-HIV cryptosporidial diarrhea with azithromycin. | 1995 | Ann Pharmacother | pmid:8845560 |